For instance, PCa with enhanced PI3K/AKT/mTOR signaling due to DAB2IP downregulation may be more sensitive to combined treatment with PI3K inhibitors and AR pathway inhibitors, such as enzalutamide and abiraterone [117,118]. Here, DAB2IP is linked to posterior cortical atrophy.